{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:22:12Z","timestamp":1794633732417,"version":"4.9.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Seattle Translational Tumor Research PDX Annotation Support Grant"},{"name":"Career Development Award support from the Radiological Society of North America","id":[{"id":"https:\/\/ror.org\/00rj4x019","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Intramural Research Program of the National Institutes of Health"},{"name":"The Mark Foundation for Cancer Research","award":["22-003-AS"],"award-info":[{"award-number":["22-003-AS"]}],"id":[{"id":"https:\/\/ror.org\/00v7th354","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIH \/ NCI Research Program Project Grant","award":["P01 CA225517"],"award-info":[{"award-number":["P01 CA225517"]}]},{"name":"NIH \/ NCI Cancer Center Support Grant","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}]},{"name":"Kelsey Dickson Team Science Courage Research Team Award","award":["#15CHAS04"],"award-info":[{"award-number":["#15CHAS04"]}]},{"name":"MCC Patient Gift Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is a major unmet need to develop therapies for patients whose tumors do not respond to PD-1 blockade. Inhibition of the ATR-mediated DNA replication checkpoint has been reported to augment antitumor immunity, although the underlying mechanisms remain poorly understood, particularly in cGAS-STING-deficient tumors. Here, we investigated the effects of ATR inhibition (ATRi) on tumor immunogenicity in Merkel cell carcinoma (MCC), an aggressive skin cancer commonly driven by Merkel cell polyomavirus (MCPyV). Among 92 primary MCC tumors, Ki-67 positivity was observed in 50% of MCPyV-positive and 83% of MCPyV-negative tumor cells, suggesting reliance on ATR-mediated replication stress responses. Notably, MCC frequently exhibits cGAS-STING deficiency, especially in MCPyV-positive tumors. In representative MCPyV-positive and -negative MCC cell lines, ATRi enhanced cytotoxicity and, alone or combined with low-dose radiation, induced proinflammatory NF-\u03baB transcriptional programs. These included increased expression of MHC class I, antigen-processing machinery, interleukins, chemokines, and interferon-related genes. ATRi also increased surface calreticulin exposure and subsequent phagocytosis by human monocyte-derived macrophages. These findings support ATRi-mediated immune reprogramming in MCC cells through an NF-\u03baB signaling cascade, regardless of cGAS\u2013STING functional status. These observations support clinical evaluation of ATR inhibitors in immunotherapy-refractory disease (NCT05947500) and suggest candidate biomarkers of therapeutic response.<\/jats:p>","DOI":"10.1038\/s41698-026-01688-4","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:53:25Z","timestamp":1789239205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ATR inhibition induces NF-\u03baB-dependent immunogenicity in Merkel cell carcinoma independent of cGAS-STING"],"prefix":"10.1038","volume":"10","author":[{"given":"Rashmi","family":"Bhakuni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan W.","family":"Newell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid A.","family":"Garman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan T.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Gilad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Brownell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"1688_CR1","doi-asserted-by":"publisher","unstructured":"Goff, P. H. et al. Intersection of two checkpoints: could inhibiting the DNA damage response checkpoint rescue immune checkpoint-refractory cancer? Cancers 13 https:\/\/doi.org\/10.3390\/cancers13143415 (2021).","DOI":"10.3390\/cancers13143415"},{"key":"1688_CR2","doi-asserted-by":"publisher","unstructured":"Dimitriou, F., Hauschild, A., Mehnert, J. M. & Long, G. V. Double trouble: immunotherapy doublets in melanoma-approved and novel combinations to optimize treatment in advanced melanoma. Am. Soc. Clin. Oncol. Educ. Book, 1\u201322 https:\/\/doi.org\/10.1200\/EDBK_351123 (2022).","DOI":"10.1200\/EDBK_351123"},{"key":"1688_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 https:\/\/doi.org\/10.1016\/j.ccell.2020.03.017 (2020).","journal-title":"Cancer Cell"},{"key":"1688_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 https:\/\/doi.org\/10.1016\/j.cell.2017.01.017 (2017).","journal-title":"Cell"},{"key":"1688_CR5","doi-asserted-by":"publisher","unstructured":"Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P. & Hu-Lieskivan, S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am. Soc. Clin. Oncol. Educ. Book, 147\u2013164 https:\/\/doi.org\/10.1200\/EDBK_240837 (2019).","DOI":"10.1200\/EDBK_240837"},{"key":"1688_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","volume":"23","author":"M De Palma","year":"2013","unstructured":"De Palma, M. & Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277\u2013286 https:\/\/doi.org\/10.1016\/j.ccr.2013.02.013 (2013).","journal-title":"Cancer Cell"},{"key":"1688_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2020.00091","volume":"10","author":"AR Almutairi","year":"2020","unstructured":"Almutairi, A. R., McBride, A., Slack, M., Erstad, B. L. & Abraham, I. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol. 10, 91 https:\/\/doi.org\/10.3389\/fonc.2020.00091 (2020).","journal-title":"Front Oncol."},{"key":"1688_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing, P. et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J. Immunother. Cancer 7, 341 https:\/\/doi.org\/10.1186\/s40425-019-0779-6 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1688_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","volume":"400","author":"S Kim","year":"2022","unstructured":"Kim, S. et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet 400, 1008\u20131019 https:\/\/doi.org\/10.1016\/S0140-6736(22)01659-2 (2022).","journal-title":"Lancet"},{"key":"1688_CR10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00262-020-02832-0","volume":"70","author":"V Glutsch","year":"2021","unstructured":"Glutsch, V. et al. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. Cancer Immunol. Immunother. 70, 2087\u20132093 https:\/\/doi.org\/10.1007\/s00262-020-02832-0 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"1688_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s40425-019-0661-6","volume":"7","author":"J LoPiccolo","year":"2019","unstructured":"LoPiccolo, J. et al. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. J. Immunother. Cancer 7, 170 https:\/\/doi.org\/10.1186\/s40425-019-0661-6 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1688_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-018-0396-9","volume":"6","author":"J Appelbaum","year":"2018","unstructured":"Appelbaum, J. et al. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J. Immunother. Cancer 6, 82 https:\/\/doi.org\/10.1186\/s40425-018-0396-9 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1688_CR13","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde, A. et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat. Med 29, 2278\u20132285 https:\/\/doi.org\/10.1038\/s41591-023-02498-y (2023).","journal-title":"Nat. Med"},{"key":"1688_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/CJI.0000000000000432","volume":"45","author":"SZ Shalhout","year":"2022","unstructured":"Shalhout, S. Z. et al. A retrospective study of ipilimumab plus nivolumab in anti-PD-L1\/PD-1 refractory merkel cell carcinoma. J. Immunother. 45, 299\u2013302 https:\/\/doi.org\/10.1097\/CJI.0000000000000432 (2022).","journal-title":"J. Immunother."},{"key":"1688_CR15","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1111\/1346-8138.15621","volume":"48","author":"K Khaddour","year":"2021","unstructured":"Khaddour, K., Rosman, I. S., Dehdashti, F. & Ansstas, G. Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy? J. Dermatol 48, e80\u2013e81 https:\/\/doi.org\/10.1111\/1346-8138.15621 (2021).","journal-title":"J. Dermatol"},{"key":"1688_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1242\/jcs.035105","volume":"122","author":"B Shiotani","year":"2009","unstructured":"Shiotani, B. & Zou, L. ATR signaling at a glance. J. Cell Sci. 122, 301\u2013304 https:\/\/doi.org\/10.1242\/jcs.035105 (2009).","journal-title":"J. Cell Sci."},{"key":"1688_CR17","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1172\/JCI96519","volume":"128","author":"FP Vendetti","year":"2018","unstructured":"Vendetti, F. P. et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J. Clin. Investig. 128, 3926\u20133940 https:\/\/doi.org\/10.1172\/JCI96519 (2018).","journal-title":"J. Clin. Investig."},{"key":"1688_CR18","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","volume":"25","author":"MT Dillon","year":"2019","unstructured":"Dillon, M. T. et al. ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clin. Cancer Res. 25, 3392\u20133403 https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1821 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1688_CR19","doi-asserted-by":"publisher","unstructured":"Sheng, H. et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J. Immunother Cancer 8 https:\/\/doi.org\/10.1136\/jitc-2019-000340 (2020).","DOI":"10.1136\/jitc-2019-000340"},{"key":"1688_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27057-2","volume":"12","author":"J Szydzik","year":"2021","unstructured":"Szydzik, J. et al. ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. Nat. Commun. 12, 6813 https:\/\/doi.org\/10.1038\/s41467-021-27057-2 (2021).","journal-title":"Nat. Commun."},{"key":"1688_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45996-4","volume":"15","author":"EL Hardaker","year":"2024","unstructured":"Hardaker, E. L. et al. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat. Commun. 15, 1700 https:\/\/doi.org\/10.1038\/s41467-024-45996-4 (2024).","journal-title":"Nat. Commun."},{"key":"1688_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51236-6","volume":"15","author":"EC Patin","year":"2024","unstructured":"Patin, E. C. et al. Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy. Nat. Commun. 15, 6923 https:\/\/doi.org\/10.1038\/s41467-024-51236-6 (2024).","journal-title":"Nat. Commun."},{"key":"1688_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim, R. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann. Oncol. 33, 193\u2013203 https:\/\/doi.org\/10.1016\/j.annonc.2021.10.009 (2022).","journal-title":"Ann. Oncol."},{"key":"1688_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","volume":"39","author":"A Thomas","year":"2021","unstructured":"Thomas, A. et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell 39, 566\u2013579.e567 https:\/\/doi.org\/10.1016\/j.ccell.2021.02.014 (2021).","journal-title":"Cancer Cell"},{"key":"1688_CR25","doi-asserted-by":"publisher","unstructured":"Patin, E. C. et al. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J. Immunother. Cancer 10 https:\/\/doi.org\/10.1136\/jitc-2021-004306 (2022).","DOI":"10.1136\/jitc-2021-004306"},{"key":"1688_CR26","doi-asserted-by":"publisher","unstructured":"Kwon, M. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J. Immunother. Cancer 10 https:\/\/doi.org\/10.1136\/jitc-2022-005041 (2022).","DOI":"10.1136\/jitc-2022-005041"},{"key":"1688_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse, B. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. 30, 716\u2013729 https:\/\/doi.org\/10.1038\/s41591-024-02808-y (2024).","journal-title":"Nat. Med."},{"key":"1688_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62249-0","volume":"16","author":"MT Dillon","year":"2025","unstructured":"Dillon, M. T. et al. Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial. Nat. Commun. 16, 7064 https:\/\/doi.org\/10.1038\/s41467-025-62249-0 (2025).","journal-title":"Nat. Commun."},{"key":"1688_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4618","volume":"27","author":"H Taniguchi","year":"2024","unstructured":"Taniguchi, H. et al. ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Sci. Adv. 27, eado4618 https:\/\/doi.org\/10.1126\/sciadv.ado4618 (2024).","journal-title":"Sci. Adv."},{"key":"1688_CR30","doi-asserted-by":"publisher","unstructured":"Ch\u2019en, P. Y. et al. Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials. J. Immunother. Cancer 13 https:\/\/doi.org\/10.1136\/jitc-2025-012660 (2025).","DOI":"10.1136\/jitc-2025-012660"},{"key":"1688_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1200\/JOP.2016.014498","volume":"12","author":"NA Vandeven","year":"2016","unstructured":"Vandeven, N. A. & Nghiem, P. Merkel cell carcinoma: an unusually immunogenic cancer proves ripe for immune therapy. J. Oncol. Pr. 12, 649\u2013650 https:\/\/doi.org\/10.1200\/JOP.2016.014498 (2016).","journal-title":"J. Oncol. Pr."},{"key":"1688_CR32","doi-asserted-by":"crossref","unstructured":"Heath, M. et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the \u201cAEIOU\u201d features. J. Am. Acad. Dermatol. 58 (2008).","DOI":"10.1016\/j.jaad.2007.11.020"},{"key":"1688_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","volume":"158","author":"AM McEvoy","year":"2022","unstructured":"McEvoy, A. M. et al. Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol 158, 382\u2013389 https:\/\/doi.org\/10.1001\/jamadermatol.2021.6096 (2022).","journal-title":"JAMA Dermatol"},{"key":"1688_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-pathmechdis-012419-032817","volume":"16","author":"JA DeCaprio","year":"2021","unstructured":"DeCaprio, J. A. Molecular pathogenesis of Merkel cell carcinoma. Annu. Rev. Pathol. 16, 69\u201391 https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012419-032817 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"1688_CR35","doi-asserted-by":"publisher","first-page":"13730","DOI":"10.1073\/pnas.1919690117","volume":"117","author":"W Liu","year":"2020","unstructured":"Liu, W. et al. Selective reactivation of STING signaling to target Merkel cell carcinoma. Proc. Natl. Acad. Sci. USA 117, 13730\u201313739 https:\/\/doi.org\/10.1073\/pnas.1919690117 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1688_CR36","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-16-1404","volume":"76","author":"T Xia","year":"2016","unstructured":"Xia, T., Konno, H. & Barber, G. N. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 76, 6747\u20136759 https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1404 (2016).","journal-title":"Cancer Res."},{"key":"1688_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-14-0005","volume":"2","author":"KG Paulson","year":"2014","unstructured":"Paulson, K. G. et al. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol. Res. 2, 1071\u20131079 https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0005 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"1688_CR38","doi-asserted-by":"publisher","first-page":"e1338237","DOI":"10.1080\/2162402X.2017.1338237","volume":"6","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf, D. et al. Immune evasion mechanisms and immune checkpoint inhibition in advanced Merkel cell carcinoma. Oncoimmunology 6, e1338237 https:\/\/doi.org\/10.1080\/2162402X.2017.1338237 (2017).","journal-title":"Oncoimmunology"},{"key":"1688_CR39","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jid.2016.10.028","volume":"137","author":"AS Moshiri","year":"2017","unstructured":"Moshiri, A. S. et al. Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. J. Investig. Dermatol. 137, 819\u2013827 https:\/\/doi.org\/10.1016\/j.jid.2016.10.028 (2017).","journal-title":"J. Investig. Dermatol."},{"key":"1688_CR40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase. JAMA Oncol. 7, 739\u2013743 https:\/\/doi.org\/10.1001\/jamaoncol.2020.7684 (2021).","journal-title":"JAMA Oncol."},{"key":"1688_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395\u2013405 https:\/\/doi.org\/10.1200\/JCO.19.01638 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1688_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/pcan.2016.12","volume":"19","author":"MS Tretiakova","year":"2016","unstructured":"Tretiakova, M. S. et al. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer Prostatic Dis. 19, 264\u20132270 https:\/\/doi.org\/10.1038\/pcan.2016.12 (2016).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1688_CR43","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs5.50175","volume":"3","author":"I Pergolini","year":"2019","unstructured":"Pergolini, I. et al. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. BJS Open 3, 646\u2013655 https:\/\/doi.org\/10.1002\/bjs5.50175 (2019).","journal-title":"BJS Open"},{"key":"1688_CR44","first-page":"155","volume":"84","author":"A Berenzi","year":"1992","unstructured":"Berenzi, A. et al. Ki67 immunohistochemical evaluation in colorectal cancer and normal colonic mucosa. Possible clinical applications. Pathologica Pathologica 84, 155\u2013163 (1992).","journal-title":"Pathologica Pathologica"},{"key":"1688_CR45","first-page":"5339","volume":"15","author":"Q Zhu","year":"2023","unstructured":"Zhu, Q., Zhang, J., Xu, D. & Zhao, R. Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients. Am. J. Transl. Res. 15, 5339\u20135346 (2023).","journal-title":"Am. J. Transl. Res."},{"key":"1688_CR46","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/CM9.0000000000000109","volume":"132","author":"HY Wang","year":"2019","unstructured":"Wang, H. Y. et al. Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors. Chin. Med. J. 132, 551\u2013561 https:\/\/doi.org\/10.1097\/CM9.0000000000000109 (2019).","journal-title":"Chin. Med. J."},{"key":"1688_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-140","volume":"10","author":"RG Ladstein","year":"2010","unstructured":"Ladstein, R. G., Bachmann, I. M., Straume, O. & Akslen, L. A. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10, 140 https:\/\/doi.org\/10.1186\/1471-2407-10-140 (2010).","journal-title":"BMC Cancer"},{"key":"1688_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cell Syst."},{"key":"1688_CR49","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1200\/JCO-24-02138","volume":"43","author":"S Bhatia","year":"2025","unstructured":"Bhatia, S. et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic merkel cell carcinoma: a nonrandomized, open-label, international, multicenter phase I\/II study. J. Clin. Oncol. 43, 1137\u20131147 https:\/\/doi.org\/10.1200\/JCO-24-02138 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1688_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 https:\/\/doi.org\/10.1126\/science.adf1329 (2024).","journal-title":"Science"},{"key":"1688_CR51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 https:\/\/doi.org\/10.1126\/science.abf3363 (2021).","journal-title":"Science"},{"key":"1688_CR52","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.ccr-19-2238","volume":"26","author":"M Fabre","year":"2020","unstructured":"Fabre, M. et al. OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models. Clin. Cancer Res. 26, 3420\u20133430 https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2238 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1688_CR53","doi-asserted-by":"publisher","unstructured":"Lee, P. C. et al. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J. Clin. Investig. 132 https:\/\/doi.org\/10.1172\/JCI151666 (2022).","DOI":"10.1172\/JCI151666"},{"key":"1688_CR54","doi-asserted-by":"publisher","unstructured":"Qin, T. et al. Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge. J. Clin. Investig. 135 https:\/\/doi.org\/10.1172\/JCI181671 (2025).","DOI":"10.1172\/JCI181671"},{"key":"1688_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432.CCR-18-1999","volume":"25","author":"M Ameratunga","year":"2019","unstructured":"Ameratunga, M., Kipps, E., Okines, A. F. C. & Lopez, J. S. To cycle or fight-CDK4\/6 inhibitors at the crossroads of anticancer immunity. Clin. Cancer Res. 25, 21\u201328 https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1999 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1688_CR56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel, S. et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475 https:\/\/doi.org\/10.1038\/nature23465 (2017).","journal-title":"Nature"},{"key":"1688_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 79, 311\u2013319 https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1003 (2019).","journal-title":"Cancer Res"},{"key":"1688_CR58","doi-asserted-by":"publisher","unstructured":"Hu, M. et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation. J. Clin. Investig. 131 https:\/\/doi.org\/10.1172\/JCI139333 (2021).","DOI":"10.1172\/JCI139333"},{"key":"1688_CR59","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated t-cell activation in small cell lung cancer. Cancer Discov. 9, 646\u2013661 https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1020 (2019).","journal-title":"Cancer Discov."},{"key":"1688_CR60","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1541-7786.MCR-21-0612","volume":"20","author":"MI Carr","year":"2022","unstructured":"Carr, M. I. et al. DNA-PK inhibitor peposertib amplifies radiation-induced inflammatory micronucleation and enhances TGFbeta\/PD-L1 targeted cancer immunotherapy. Mol. Cancer Res 20, 568\u2013582 https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0612 (2022).","journal-title":"Mol. Cancer Res"},{"key":"1688_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110814","volume":"39","author":"H Taniguchi","year":"2022","unstructured":"Taniguchi, H. et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 39, 110814 https:\/\/doi.org\/10.1016\/j.celrep.2022.110814 (2022).","journal-title":"Cell Rep."},{"key":"1688_CR62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/bs.ircmb.2018.08.006","volume":"344","author":"T Medler","year":"2019","unstructured":"Medler, T. et al. Activating the nucleic acid-sensing machinery for anticancer immunity. Int. Rev. Cell Mol. Biol. 344, 173\u2013214 https:\/\/doi.org\/10.1016\/bs.ircmb.2018.08.006 (2019).","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"1688_CR63","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1101\/gad.348314.121","volume":"35","author":"D Pilger","year":"2021","unstructured":"Pilger, D., Seymour, L. W. & Jackson, S. P. Interfaces between cellular responses to DNA damage and cancer immunotherapy. Genes Dev. 35, 602\u2013618 https:\/\/doi.org\/10.1101\/gad.348314.121 (2021).","journal-title":"Genes Dev."},{"key":"1688_CR64","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1016\/j.molcel.2023.09.022","volume":"83","author":"KA Cimprich","year":"2023","unstructured":"Cimprich, K. A. et al. The crosstalk between DNA repair and immune responses. Mol. Cell 83, 3582\u20133587 https:\/\/doi.org\/10.1016\/j.molcel.2023.09.022 (2023).","journal-title":"Mol. Cell"},{"key":"1688_CR65","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1016\/j.molcel.2025.08.030","volume":"85","author":"A Shim","year":"2025","unstructured":"Shim, A., Chen, Y. & Maciejowski, J. Activation and regulation of cGAS-STING signaling in cancer cells. Mol. Cell 85, 3807\u20133822 https:\/\/doi.org\/10.1016\/j.molcel.2025.08.030 (2025).","journal-title":"Mol. Cell"},{"key":"1688_CR66","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","volume":"14","author":"T Xia","year":"2016","unstructured":"Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14, 282\u2013297 https:\/\/doi.org\/10.1016\/j.celrep.2015.12.029 (2016).","journal-title":"Cell Rep."},{"key":"1688_CR67","doi-asserted-by":"publisher","unstructured":"Pulliam, T. et al. Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses. J. Immunother. Cancer 12 https:\/\/doi.org\/10.1136\/jitc-2024-009803 (2024).","DOI":"10.1136\/jitc-2024-009803"},{"key":"1688_CR68","doi-asserted-by":"publisher","first-page":"9092","DOI":"10.1073\/pnas.161281798","volume":"98","author":"P Nghiem","year":"2001","unstructured":"Nghiem, P., Park, P. K., Kim, Y., Vaziri, C. & Schreiber, S. L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. USA 98, 9092\u20139097 https:\/\/doi.org\/10.1073\/pnas.161281798 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1688_CR69","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz, L. M. & Zou, L. Molecular pathways: targeting ATR in cancer therapy. Clin. Cancer Res. 21, 4780\u20134785 https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0479 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1688_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112567","volume":"28","author":"JL Schnabel","year":"2025","unstructured":"Schnabel, J. L. et al. IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma. iScience 28, 112567 https:\/\/doi.org\/10.1016\/j.isci.2025.112567 (2025).","journal-title":"iScience"},{"key":"1688_CR71","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi, N. Y. L. et al. Targeting ATR in patients with cancer. Nat. Rev. Clin. Oncol. 21, 278\u2013293 https:\/\/doi.org\/10.1038\/s41571-024-00863-5 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1688_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117804","volume":"296","author":"S Guo","year":"2025","unstructured":"Guo, S. et al. Research progress of ATR small molecule inhibitors in cancer therapy. Eur. J. Med Chem. 296, 117804 https:\/\/doi.org\/10.1016\/j.ejmech.2025.117804 (2025).","journal-title":"Eur. J. Med Chem."},{"key":"1688_CR73","doi-asserted-by":"publisher","unstructured":"Dillon, M. T. et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J. Clin. Investig. 134 https:\/\/doi.org\/10.1172\/JCI175369 (2024).","DOI":"10.1172\/JCI175369"},{"key":"1688_CR74","doi-asserted-by":"publisher","unstructured":"Yu, Q. et al. Pharmacological induction of MHC-I expression in tumor cells revitalizes T cell antitumor immunity. JCI Insight 9 https:\/\/doi.org\/10.1172\/jci.insight.177788 (2024).","DOI":"10.1172\/jci.insight.177788"},{"key":"1688_CR75","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-024-01417-0","volume":"32","author":"E Bournique","year":"2025","unstructured":"Bournique, E. et al. ATM and IRAK1 orchestrate two distinct mechanisms of NF-kappaB activation in response to DNA damage. Nat. Struct. Mol. Biol. 32, 740\u2013755 https:\/\/doi.org\/10.1038\/s41594-024-01417-0 (2025).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1688_CR76","doi-asserted-by":"publisher","unstructured":"Goh, N. L. L. et al. Checkpoint kinase 1 inhibitor combined with low dose hydroxyurea promotes ATM-activated NF-kappaB-dependent pro-inflammatory chemokine expression in melanomas. Cancers 17 https:\/\/doi.org\/10.3390\/cancers17111817 (2025).","DOI":"10.3390\/cancers17111817"},{"key":"1688_CR77","doi-asserted-by":"publisher","unstructured":"Hunter, J. E. et al. Regulation of checkpoint kinase signalling and tumorigenesis by the NF-\u03baB regulated gene, CLSPN. bioRxiv https:\/\/doi.org\/10.1101\/358291 (2018).","DOI":"10.1101\/358291"},{"key":"1688_CR78","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2117321","volume":"11","author":"M Lopez-Pelaez","year":"2022","unstructured":"Lopez-Pelaez, M. et al. Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation. Oncoimmunology 11, 2117321 https:\/\/doi.org\/10.1080\/2162402X.2022.2117321 (2022).","journal-title":"Oncoimmunology"},{"key":"1688_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/oncotarget.28551","volume":"16","author":"M Lozinski","year":"2024","unstructured":"Lozinski, M. et al. ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. Oncotarget 16, 1\u201318 https:\/\/doi.org\/10.18632\/oncotarget.28551 (2024).","journal-title":"Oncotarget"},{"key":"1688_CR80","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104036","volume":"39","author":"X Feng","year":"2020","unstructured":"Feng, X. et al. ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways. EMBO J. 39, e104036 https:\/\/doi.org\/10.15252\/embj.2019104036 (2020).","journal-title":"EMBO J."},{"key":"1688_CR81","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.trecan.2018.09.006","volume":"4","author":"L Spel","year":"2018","unstructured":"Spel, L., Schiepers, A. & Boes, M. NF\u03baB and MHC-1 interplay in neuroblastoma and immunotherapy. Trends Cancer 4, 715\u2013717 https:\/\/doi.org\/10.1016\/j.trecan.2018.09.006 (2018).","journal-title":"Trends Cancer"},{"key":"1688_CR82","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1158\/0008-5472.CAN-09-2582","volume":"70","author":"M Forloni","year":"2010","unstructured":"Forloni, M. et al. NF-\u03baB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res. 70, 916\u2013924 https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2582 (2010).","journal-title":"Cancer Res."},{"key":"1688_CR83","doi-asserted-by":"publisher","first-page":"e46928","DOI":"10.1371\/journal.pone.0046928","volume":"7","author":"S Lorenzi","year":"2012","unstructured":"Lorenzi, S. et al. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One 7, e46928 https:\/\/doi.org\/10.1371\/journal.pone.0046928 (2012).","journal-title":"PLoS One"},{"key":"1688_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 12, 636568 https:\/\/doi.org\/10.3389\/fimmu.2021.636568 (2021).","journal-title":"Front Immunol."},{"key":"1688_CR85","doi-asserted-by":"publisher","first-page":"e2025840118","DOI":"10.1073\/pnas.2025840118","volume":"118","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Activation of NF-\u03baB and p300\/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc. Natl. Acad. Sci. USA 118, e2025840118 https:\/\/doi.org\/10.1073\/pnas.2025840118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1688_CR86","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.immuni.2024.02.019","volume":"57","author":"S Dvorkin","year":"2024","unstructured":"Dvorkin, S., Cambier, S., Volkman, H. E. & Stetson, D. B. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity 57, 718\u2013730 https:\/\/doi.org\/10.1016\/j.immuni.2024.02.019 (2024).","journal-title":"Immunity"},{"key":"1688_CR87","doi-asserted-by":"publisher","unstructured":"Cornice, J. et al. NF-\u03baB: Governing macrophages in cancer. Genes 15 https:\/\/doi.org\/10.3390\/genes15020197 (2024).","DOI":"10.3390\/genes15020197"},{"key":"1688_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-\u03baB signaling in inflammation. Signal Transduct. Target Ther. 2, 17023 https:\/\/doi.org\/10.1038\/sigtrans.2017.23 (2017).","journal-title":"Signal Transduct. Target Ther."},{"key":"1688_CR89","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3389\/fimmu.2017.01034","volume":"8","author":"R Osman","year":"2017","unstructured":"Osman, R., Tacnet-Delorme, P., Kleman, J. P., Millet, A. & Frachet, P. Calreticulin release at an early stage of death modulates the clearance by macrophages of apoptotic cells. Front Immunol. 8, 1034 https:\/\/doi.org\/10.3389\/fimmu.2017.01034 (2017).","journal-title":"Front Immunol."},{"key":"1688_CR90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/scitranslmed.3001375","volume":"2","author":"MP Chao","year":"2010","unstructured":"Chao, M. P. et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63\u201394 https:\/\/doi.org\/10.1126\/scitranslmed.3001375 (2010).","journal-title":"Sci. Transl. Med."},{"key":"1688_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06807-9","volume":"9","author":"DV Krysko","year":"2018","unstructured":"Krysko, D. V., Ravichandran, K. S. & Vandenabeele, P. Macrophages regulate the clearance of living cells by calreticulin. Nat. Commun. 9, 4644 https:\/\/doi.org\/10.1038\/s41467-018-06807-9 (2018).","journal-title":"Nat. Commun."},{"key":"1688_CR92","doi-asserted-by":"publisher","DOI":"10.1093\/toxres\/tfae044","volume":"13","author":"F Sewell","year":"2024","unstructured":"Sewell, F. et al. New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption. Toxicol. Res. 13, tfae044 https:\/\/doi.org\/10.1093\/toxres\/tfae044 (2024).","journal-title":"Toxicol. Res."},{"key":"1688_CR93","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ijrobp.2023.12.012","volume":"118","author":"DA Odhiambo","year":"2024","unstructured":"Odhiambo, D. A. et al. Preclinical evaluation of the ATR inhibitor BAY 1895344 as a radiosensitizer for head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 118, 1315\u20131327 https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.012 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1688_CR94","unstructured":"Bhakuni, R. et al. in Regular and Young Investigator Award Abstracts 13 A1\u2013A1534 (J Immunother Cancer, 2025)."},{"key":"1688_CR95","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat. Med. 29, 1400\u20131411 https:\/\/doi.org\/10.1038\/s41591-023-02399-0 (2023).","journal-title":"Nat. Med."},{"key":"1688_CR96","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/2159-8290.CD-24-1500","volume":"15","author":"TA Yap","year":"2025","unstructured":"Yap, T. A. et al. Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects. Cancer Discov. 15, 2019\u20132035 https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1500 (2025).","journal-title":"Cancer Discov."},{"key":"1688_CR97","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/cam4.458","volume":"4","author":"JG Iyer","year":"2015","unstructured":"Iyer, J. G. et al. Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med. 4, 1161\u20131170 https:\/\/doi.org\/10.1002\/cam4.458 (2015).","journal-title":"Cancer Med."},{"key":"1688_CR98","doi-asserted-by":"publisher","first-page":"e165615","DOI":"10.1172\/jci.insight.165615","volume":"8","author":"FP Vendetti","year":"2023","unstructured":"Vendetti, F. P. et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8, e165615 https:\/\/doi.org\/10.1172\/jci.insight.165615 (2023).","journal-title":"JCI Insight"},{"key":"1688_CR99","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","volume":"24","author":"Y Drew","year":"2025","unstructured":"Drew, Y., Zenke, F. T. & Curtin, N. J. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat. Rev. Drug Discov. 24, 19\u201339 https:\/\/doi.org\/10.1038\/s41573-024-01060-w (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1688_CR100","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.seminoncol.2016.06.001","volume":"43","author":"U Banerji","year":"2016","unstructured":"Banerji, U. & Workman, P. Critical parameters in targeted drug development: the pharmacological audit trail. Semin Oncol. 43, 436\u2013445 https:\/\/doi.org\/10.1053\/j.seminoncol.2016.06.001 (2016).","journal-title":"Semin Oncol."},{"key":"1688_CR101","doi-asserted-by":"publisher","first-page":"21890","DOI":"10.1021\/acs.jmedchem.4c01595","volume":"67","author":"CL Carroll","year":"2024","unstructured":"Carroll, C. L. et al. Discovery of ART0380, a potent and selective ATR kinase inhibitor undergoing phase 2 clinical studies for the treatment of advanced or metastatic solid cancers. J. Med Chem. 67, 21890\u201321904 https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01595 (2024).","journal-title":"J. Med Chem."},{"key":"1688_CR102","doi-asserted-by":"publisher","first-page":"CT267","DOI":"10.1158\/1538-7445.AM2025-CT267","volume":"85","author":"S Ulahannan","year":"2025","unstructured":"Ulahannan, S. et al. Abstract CT267: first results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors. Cancer Res 85, CT267 https:\/\/doi.org\/10.1158\/1538-7445.AM2025-CT267 (2025).","journal-title":"Cancer Res"},{"key":"1688_CR103","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 https:\/\/doi.org\/10.1093\/bioinformatics\/btp616 (2010).","journal-title":"Bioinformatics"},{"key":"1688_CR104","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1214\/16-AOAS920","volume":"10","author":"B Phipson","year":"2016","unstructured":"Phipson, B., Lee, S., Majewski, I. J., Alexander, W. S. & Smyth, G. K. Robust Hyperparameter Estimation Protects against Hypervariable Genes and Improves Power to Detect Differential Expression. Ann. Appl Stat. 10, 946\u2013963 https:\/\/doi.org\/10.1214\/16-AOAS920 (2016).","journal-title":"Ann. Appl Stat."},{"key":"1688_CR105","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant graphics for data analysis. (Springer-Verlag, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"1688_CR106","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1093\/nar\/gkaa802","volume":"48","author":"DD Bhuva","year":"2020","unstructured":"Bhuva, D. D., Cursons, J. & Davis, M. J. Stable gene expression for normalisation and single-sample scoring. Nucleic Acids Res. 48, e113 https:\/\/doi.org\/10.1093\/nar\/gkaa802 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1688_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2024.103215","volume":"5","author":"X Wu","year":"2024","unstructured":"Wu, X., Wang, Z., Shern, T. & Zhang, H. Efferocytosis assay to quantify the engulfment and acidification of apoptotic cells by macrophages using flow cytometry. STAR Protoc. 5, 103215 https:\/\/doi.org\/10.1016\/j.xpro.2024.103215 (2024).","journal-title":"STAR Protoc."},{"key":"1688_CR108","doi-asserted-by":"publisher","unstructured":"Galluzzi, L. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother Cancer 8 https:\/\/doi.org\/10.1136\/jitc-2019-000337 (2020).","DOI":"10.1136\/jitc-2019-000337"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01688-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:30:46Z","timestamp":1794630646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01688-4","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.G.: Oren Gilad serves as President and Chief Executive Officer at Aprea Therapeutics, Doylestown, PA. E.J.B.: Eric J. Brown is a Scientific Advisory Board member for BreakSight and former Scientific Consultant and Advisory Board Member for ATRIN Pharmaceuticals and Aprea Therapeutics. All other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"368"}}